Atlantic Union Bankshares Corp Purchases 11,384 Shares of Edwards Lifesciences Corporation $EW

Atlantic Union Bankshares Corp increased its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 2,240.9% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 11,892 shares of the medical research company’s stock after acquiring an additional 11,384 shares during the period. Atlantic Union Bankshares Corp’s holdings in Edwards Lifesciences were worth $925,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of EW. Econ Financial Services Corp bought a new stake in shares of Edwards Lifesciences during the 2nd quarter valued at $889,000. Fjarde AP Fonden Fourth Swedish National Pension Fund grew its stake in shares of Edwards Lifesciences by 7.0% during the third quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 137,835 shares of the medical research company’s stock worth $10,719,000 after purchasing an additional 9,069 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its holdings in Edwards Lifesciences by 13.2% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 86,235 shares of the medical research company’s stock valued at $6,706,000 after purchasing an additional 10,078 shares during the last quarter. OMERS ADMINISTRATION Corp lifted its stake in Edwards Lifesciences by 97.3% in the second quarter. OMERS ADMINISTRATION Corp now owns 44,504 shares of the medical research company’s stock valued at $3,481,000 after buying an additional 21,950 shares during the period. Finally, Arkadios Wealth Advisors acquired a new position in shares of Edwards Lifesciences during the 2nd quarter worth about $300,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, CFO Scott B. Ullem sold 13,000 shares of Edwards Lifesciences stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $83.08, for a total value of $1,080,040.00. Following the completion of the transaction, the chief financial officer owned 39,898 shares of the company’s stock, valued at $3,314,725.84. This trade represents a 24.58% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Daniel J. Lippis sold 1,020 shares of Edwards Lifesciences stock in a transaction dated Monday, November 10th. The stock was sold at an average price of $82.55, for a total value of $84,201.00. Following the transaction, the vice president owned 22,002 shares of the company’s stock, valued at $1,816,265.10. The trade was a 4.43% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 57,824 shares of company stock worth $4,863,323. Insiders own 1.29% of the company’s stock.

Wall Street Analyst Weigh In

EW has been the topic of a number of analyst reports. Wells Fargo & Company set a $100.00 price target on shares of Edwards Lifesciences in a research report on Thursday, December 18th. The Goldman Sachs Group reiterated a “buy” rating and issued a $108.00 target price on shares of Edwards Lifesciences in a report on Friday, January 9th. Barclays reissued an “overweight” rating and issued a $104.00 price target (up previously from $103.00) on shares of Edwards Lifesciences in a report on Monday, January 12th. Evercore ISI reaffirmed an “outperform” rating and set a $94.00 price objective on shares of Edwards Lifesciences in a research note on Monday, January 5th. Finally, BTIG Research reissued a “buy” rating and issued a $103.00 target price (up from $100.00) on shares of Edwards Lifesciences in a research note on Thursday, December 4th. Three research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $96.77.

Edwards Lifesciences Stock Performance

Shares of NYSE EW opened at $79.75 on Thursday. The stock has a market capitalization of $46.28 billion, a PE ratio of 34.38, a price-to-earnings-growth ratio of 3.16 and a beta of 0.94. Edwards Lifesciences Corporation has a 52 week low of $65.94 and a 52 week high of $87.89. The stock has a 50 day moving average price of $84.48 and a 200 day moving average price of $81.10. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.29 and a current ratio of 4.00.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.